ITD 1

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    TGFβ signalling has been shown to be important at an early stage in cardiac development, with most previous investigations focussing on the role during formation of the cardiac cushions. These cushions, which develop between embryonic day E9.5 and E11.5 in the mouse, are essential precursors of the mature valves, and intimately involved in septation. It is well known that TGFβ signalling promotes endothelial to mesenchymal transition, and subsequent migration of mesenchymal cells to the cardiac jelly. ITD-1 is the first selective TGFβ inhibitor.In vitro: ITD-1 has been used to evaluate TGFβ involvement in mesoderm formation and cardiopoietic differentiation, which occur sequentially during early development, indicating an essential role in both processes in ESC cultures. ITD-1 selectively enhanced the uncommitted mesoderm differentiation to cardiomyocytes, but not to vascular smooth muscle and endothelial cells. In summary, ITD-1 is the first selective TGFβ inhibitor and reveals an unexpected role for TGFβ signaling in controlling the differentiation of cardiomyocyte from multipotent cardiovascular precursors [1]. In vivo: So far, ITD-1 has not been subjected to conduct animal in vivo study. Clinical trial: Up to now, ITD-1 is still in the preclinical development stage.
- Properties
  - Alternative Name
    
    (Z)-1-(5-(tert-butyl)isoxazol-3(2H)-ylidene)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea
    
    CAS Number
    
    1099644-42-4
    
    Molecular Formula
    
    C29H32N6O4S
    
    Molecular Weight
    
    560.67
    
    Appearance
    
    A solid
    
    Purity
    
    99.71%
    
    Solubility
    
    ≥28.05 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only

ITD 1

Background

We Also Recommend

Entrectinib

Molidustat (BAY85-3934)

TAK960